On March 23, 2023,
Jefferies
upgraded
their outlook for Inozyme Pharma (NASDAQ:INZY) from Hold to Buy.
Analyst Price Forecast Suggests 489.65% Upside
As of March 24, 2023,
the common one-year price target for Inozyme Pharma is $19.46.
The forecasts vary from a low of $4.54 to a excessive of $42.00.
The common worth goal represents a rise of 489.65% from its newest reported closing worth of $3.30.
See our leaderboard of companies with the biggest worth goal upside.
The projected annual income for Inozyme Pharma
is $0MM.
The projected annual non-GAAP EPS
is -$1.83.
What are Large Shareholders Doing?
Sofinnova Investments
holds 3,655K shares
representing 9.05% possession of the corporate.
No change within the final quarter.
Deep Track Capital
holds 3,250K shares
representing 8.05% possession of the corporate.
No change within the final quarter.
Adage Capital Partners Gp, L.l.c.
holds 3,100K shares
representing 7.67% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 2,597K shares, representing
a rise
of 16.24%.
The agency
decreased
its portfolio allocation in INZY by 54.89% over the past quarter.
Rock Springs Capital Management
holds 3,086K shares
representing 7.64% possession of the corporate.
In it is prior submitting, the agency reported proudly owning 2,808K shares, representing
a rise
of 9.02%.
The agency
decreased
its portfolio allocation in INZY by 59.88% over the past quarter.
VR Adviser
holds 2,710K shares
representing 6.71% possession of the corporate.
No change within the final quarter.
What is the Fund Sentiment?
There are 69 funds or institutions reporting positions in Inozyme Pharma.
This is a lower
of
19
proprietor(s) or 21.59% within the final quarter.
Average portfolio weight of all funds devoted to INZY is 0.04%,
a lower
of 55.43%.
Total shares owned by establishments decreased
within the final three months by 3.49% to 29,941K shares.
The put/call ratio of INZY is 1.63, indicating a
bearish
outlook.
Inozyme Pharma Background Information
(This description is offered by the corporate.)
Inozyme Pharma is a uncommon illness biopharmaceutical firm growing novel therapeutics for the therapy of illnesses of irregular mineralization. Through our in-depth understanding of the organic pathways concerned in mineralization, firm is pursuing the event of therapeutics to handle the underlying causes of those debilitating illnesses. It is effectively established that two genes, ENPP1 and ABCC6, play key roles in a essential mineralization pathway and that defects in these genes result in irregular mineralization. Inozyme is initially targeted on growing a novel remedy to deal with the uncommon genetic illnesses of ENPP1 and ABCC6 deficiencies.
This story initially appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.